Key result
PFO closure benefit remains uncertain in patients older than 60 with cryptogenic stroke.
Why the study?
The optimal treatment for patent foramen ovale in patients older than 60 years with cryptogenic stroke is uncertain, as prior trials focused on younger patients.
PFO associated with cryptogenic events at older ages; extends prior observations but leaves open whether closure reduces recurrence in patients >60.
A cryptogenic stroke is one that has eluded an explanation despite complete investigation aimed at uncovering a cause. Since 2003, six randomised trials have collected a large amount of data showing the benefit of patent foramen ovale (PFO) closure compared with standard medical therapy in young patients (aged 18–60 years) with cryptogenic stroke. However, new questions have now emerged concerning the best treatment for people older than 60 years. Traditionally, PFO-related stroke has been considered a disease of younger people, and excluded from the differential diagnosis in elderly patients.
No takes yet. Share an insight, caveat, or question.
David E. Thaler (2018) conducted a review in Cryptogenic stroke or transient ischaemic attack. Patent foramen ovale (PFO) closure vs. Standard medical therapy was evaluated. While patent foramen ovale closure is beneficial in young patients with cryptogenic stroke, the optimal treatment strategy for patients older than 60 years remains uncertain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: